Zacks Research Downgrades Incannex Healthcare (NASDAQ:IXHL) to Strong Sell

Posted by Doug Wharley on Oct 8th, 2026

Incannex Healthcare (NASDAQ:IXHL – Get Free Report) was downgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued on Tuesday, Zacks reports.

IXHL has been the topic of a number of other reports. Wall Street Zen cut Incannex Healthcare from a “hold” rating to a “sell” rating in a research note on Saturday, October 3rd. Alliance Global Partners assumed coverage on shares of Incannex Healthcare in a report on Monday, June 8th. They set a “buy” rating and a $18.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Incannex Healthcare in a research report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus target price of $18.00.

Read Our Latest Analysis on Incannex Healthcare

Incannex Healthcare Stock Performance

Shares of IXHL opened at $3.18 on Tuesday. The stock has a 50 day moving average price of $3.32 and a two-hundred day moving average price of $3.44. The firm has a market capitalization of $39.91 million, a P/E ratio of -1.88 and a beta of 6.97. Incannex Healthcare has a 52 week low of $2.49 and a 52 week high of $14.91.

Incannex Healthcare (NASDAQ:IXHL – Get Free Report) last announced its earnings results on Friday, September 25th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of $0.13 by ($0.27). On average, equities analysts forecast that Incannex Healthcare will post -2.63 earnings per share for the current year.

Incannex Healthcare Company Profile

(Get Free Report)

Incannex Healthcare Limited is an Australia-based clinical-stage pharmaceutical company developing therapies for conditions with significant unmet medical needs. The company’s research programs focus on cannabinoid-based medicines and psychedelic-assisted psychotherapy, with development activities spanning sleep disorders, respiratory and inflammatory diseases, pain, and mental health.

Its pipeline includes IHL-42X, an investigational combination of dronabinol and acetazolamide being developed for obstructive sleep apnea.